HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Delves Into Broader Smoking Cessation Approach

This article was originally published in The Tan Sheet

Executive Summary

FDA’s questions for comments in a notice for a public hearing on smoking cessation approaches suggest a willingness to take an expanded approach to nicotine replacement therapy approvals and indications. Discussion topics include fast-track and accelerated approval authorities for NRTs and extended use of the products.

You may also be interested in...

E-Cigarette Firm Targets Harm Reduction In Therapeutic Claim

CN Creative’s plan to include harm reduction with smoking cessation in claims for its Nicadex electronic cigarette was key to Advent Life Sciences investing in the firm, which is prepared to ask U.K. regulators for approval this summer before applying in the U.S.

Advisory Committee On NRT Indications Appears Likely Following Workshop

Speakers at a workshop on nicotine-replacement therapy point abroad for guidance on expanding indications for smoking-cessation products as an FDA official says the agency likely will put the question before an advisory committee.

NRT Petition Calls On FDA To Greatly Expand Indications, Availability

FDA's stated commitment to a public health approach to drug regulation will be put to the test by a petition to expand nicotine replacement therapy indications and availability

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts